The molecular pathogenesis of hereditary ovarian carcinoma

Cancer

Volumn 116, Issue 22, 2010, Pages 5261-5271

  Norquist, Barbara M ^a   Garcia, Rochelle L ^a   Allison, Kimberly H ^a   Jokinen, Chris H ^a   Kernochan, Lauren E ^a   Pizzi, Catherine C ^a   Barrow, Bethany J ^b   Goff, Barbara A ^a   Swisher, Elizabeth M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

BRCA1; BRCA2; fallopian tube; Ki 67; ovarian cancer; p27; p53

Indexed keywords

KI 67 ANTIGEN; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK REDUCTION; SALPINGOOOPHORECTOMY; STAINING; TP53 GENE; UTERINE TUBE; WILD TYPE;

ADULT; AGED; CELL PROLIFERATION; FALLOPIAN TUBE NEOPLASMS; FALLOPIAN TUBES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, P53; HUMANS; KI-67 ANTIGEN; LOSS OF HETEROZYGOSITY; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS;

EID: 77958488424     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25439     Document Type: Article

References (40)

1. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005; 104: 2807-2816.
2. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001; 68: 700-710.
3. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE,. Risks of cancer in BRCA-1 mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994; 343: 692-695.
4. King MC, Marks JH, Mandell JB,; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003; 302: 643-646.
5. Barakat RR, Federici MG, Saigo PE, Robson ME, Offit K, Boyd J,. Absence of premalignant histologic, molecular, or cell biological alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer. 2000; 89: 383-390.
6. Cai KQ, Klein-Szanto A, Karthik D, et al. Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations. Gynecol Oncol. 2006; 103: 719-728.
7. Piek JM, Verheijen RH, Menko FH, et al. Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition. Histopathology. 2003; 43: 26-32.
8. Carcangiu ML, Peissel B, Pasini B, Spatti G, Radice P, Manoukian S,. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol. 2006; 30: 1222-1230.
9. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007; 25: 3985-3990.
10. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B,. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 2001; 25: 1283-1289.
11. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ,. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006; 100: 58-64.
12. Lamb JD, Garcia RL, Goff BA, Paley PJ, Swisher EM,. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol. 2006; 194: 1702-1709.
13. Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P,. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol. 2002; 87: 52-56.
14. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006; 30: 230-236.
15. Powell CB, Kenley E, Chen L, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005; 23: 127-132.
16. Neuhausen SL, Marshall CJ,. Loss of heterozygosity in familial tumors from 3 BRCA1-linked kindreds. Cancer Res. 1994; 54: 6069-6072.
17. Collins N, McManus R, Wooster R, et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene. 1995; 10: 1673-1675.
18. Gudmundsson J, Johannesdottir G, Bergthorsson JT, et al. Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-13. Cancer Res. 1995; 55: 4830-4832.
19. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001; 195: 451-456.
20. Kmet LM, Cook LS, Magliocco AM,. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer. 2003; 97: 389-404.
21. Schuijer M, Berns EM,. Is TP53 dysfunction required for BRCA1-associated carcinogenesis? Mol Cell Endocrinol. 1999; 155: 143-152.
22. Schuijer M, Berns EM,. TP53 and ovarian cancer. Hum Mutat. 2003; 21: 285-291.
23. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low-and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis. Am J Surg Pathol. 2005; 29: 218-224.
24. Swisher EM, Wollan M, Mahtani SM, et al. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol. 2005; 193: 662-667.
25. Rosen AC, Ausch C, Klein M, et al. p53 expression in fallopian tube carcinomas [letter]. Cancer Lett. 2000; 156: 107.
26. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007; 211: 26-35.
27. Shaw PA, Rouzbahman M, Pizer ES, Pintilie M, Begley H,. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol. 2009; 22: 1133-1138.
28. Folkins AK, Jarboe EA, Saleemuddin A,. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol. 2008; 109: 168-173.
29. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007; 19: 3-9.
30. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007; 31: 161-169.
31. Scholzen T, Gerdes J,. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182: 311-322.
32. Brodie SG, Deng CX,. BRCA1-associated tumorigenesis: what have we learned from knockout mice? Trends Genet. 2001; 17: S18-22.
33. Sherr DJ, Roberts JM,. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999; 13: 1501-1512.
34. Williamson EA, Dadmanesh F, Koeffler HP,. BRCA1 transactivates the cyclin-dependent kinase inhibitor p27 (Kip1). Oncogene. 2002; 21: 3199-3206.
35. Kip1. Oncogene. 2006; 25: 1391-1399.
36. Kip1 protein levels independently predict outcome after breast cancer. J Clin Oncol. 2000; 18: 4045-4052.
37. Palacios J, Honrado E, Osorio A, et al. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat. 2005; 90: 5-14.
38. Agoff SN, Garcia RL, Goff BA, Swisher EM,. Follow-up of in situ and early stage fallopian tube carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA-1 or BRCA-2 mutations. Am J Surg Pathol. 2004; 28: 1112-1114.
39. Burga LN, Tung NM, Troyan SL, et al. Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. Cancer Res. 2009; 69: 1273-1278.
40. Saleemuddin A, Folkins AK, Garrett L, et al. Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations. Gynecol Oncol. 2008; 111: 226-232.